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Abstract Asthma is a chronic inflammatory disease ofthe airways involving a wide range of cells and mediators. First- 
line therapy of persistent asthma involves the use of inhaled corticosteroids to control -the underlying inflammation ofthe 
airways. Inhaled /?-agonists are also widely used in asthmatherapy and arethe mosteffective bronchodilators currently 
available.The short-acting Pz-agonists are now used on an as-needed basis for rapid relief of symptoms. In recent years, 
long-acting inhaled PI-agonists have had an increasing role in the management of asthma, particularly in patients with 
moderate to severe asthma.This class ofdrug has a long duration of action and is recommended as add-on treatmentto 
inhaled corticosteroids in the long-term control of asthma. New therapies have been added to asthma therapy as 
our understanding of the pathogenesis of asthma has increased. The use of multiple therapies necessitates a clear 
understanding of the mode of action of the drugs and any potential interaction or overlap of effect. For many people 
asthma is associated with complex therapy; thus treatment developments that simplify asthma treatment are an 
important step forward in asthma management. 
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INTRODUCTION 
Asthma is a complex condition that results from the in- 
teractions of a variety of environmental factors acting on 
a background of genetic predisposition. It is character- 
ized by airway inflammation, reversible airway obstruc- 
tion and airway hyper-responsiveness to a variety of 
stimuli. 
Asthma can also be a progressive disease that is treated 
with a range of therapies according to the severity of the 
disease. Indeed, different aspects of asthma need to be 
treated with different agents in order to achieve symptom 
control. First-line therapy involves the use of inhaled 
corticosteroids to control the underlying inflammation of 
the airways. Short-acting P-agonists provide rapid relief of 
bronchoconstriction in all patients with asthma, whereas 
long-acting /?z-agonists, which have a long duration of 
action, control asthma symptoms and can reduce the 
frequency of exacerbations when added to inhaled corti- 
costeroids (1,2). The long-acting /$-agonist formoterol has 
a unique clinical profile, combining a fast onset and long 
duration of action (3). 
Asthma treatment guidelines have been developed in 
several countries, including the USA (4,5) and the UK 
(6).The aim of the guidelines is to achieve optimal asthma 
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control with the lowest possible dose of medication. 
Within the guidelines it is recognized that inflammation 
of the airways is present even in mild persistent asthma, 
and the evidence of a role for corticosteroids in suppres- 
sing inflammation in asthma is reviewed extensively. 
Consequently, the control of inflammation has a promi- 
nent place in asthma management. 
Current guidelines recommend a stepwise approach 
to the treatment of asthma in both adults and children. 
Progression to the next step up is indicated when control 
is not achieved or is lost at the current step, while the 
patient is adherent to prescribed medication. Stepping 
up treatment involves stepping up from the use of 
short-acting P-agonists (as symptom relievers) to inhaled 
corticosteroids (as controllers of inflammation) and then 
to the use of inhaled corticosteroids and inhaled 
long-acting /‘z-agonists (4-6). Using this stepwise ap- 
proach, both the inflammatory process of asthma and 
the concomitant bronchoconstriction can be effectively 
managed (2). 
AIRWAY RESPONSE IN ASTHMA 
The early asthmatic response (EAR), which is triggered 
by exposure to inhaled antigens or irritants, causes 
bronchoconstriction.This acute response is caused when 
allergens cross-link to immunoglobulin E (IgE) bound to 
the surface of the mast cells causing the mast cells to 
release a number of inflammatory mediators, including 
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histamine, prostaglandins and cysteinyl-leukotrienes. 
This mediator release results in smooth muscle contrac- 
tion and mucosal oedema.The EAR can also be triggered 
by airborne antigens binding to sensitized mast cells on 
the mucosal surface of the airways. This type of re- 
sponse, although caused by inflammatory mediators, 
can be completely inhibited or reversed by bronchodila- 
tors such as Pz-agonists.The anti-inflammatory action of 
inhaled corticosteroids is mainly due to direct inhibition 
of transcription factors that are normally activated by in- 
flammation.Thus, they have little effect in the short term 
against the early response mechanism, which tends to 
give rise to immunological reactions (2,7). 
The late asthmatic response (LAR), which may follow 
the EAR, involves acute inflammation and swelling of the 
airway wall. Approximately 4-6 hours after an antigen 
challenge, activated neutrophils, eosinophils, mast cells 
and T lymphocytes migrate into the airways causing in- 
flammation.This in turn may lead to epithelial desquama- 
tion, changes in mucociliary function, reduced clearance 
of respiratory tract secretions, and thus airway obstruc- 
tion(2). The LAR is often followed by an increase in air- 
way hyper-responsiveness that can be measured by 
bronchial provocation with histamine or methacholine. 
AIRWAY INFLAMMATION IN 
ASTHMA 
Histological studies of the bronchial mucosa have been 
instrumental in establishing the inflammatory basis of 
asthma. These studies have highlighted the wide range 
of cells and mediators involved in the pathophysiological 
process underlying asthma. 
Bronchoalveolar lavage (BAL) studies in patients with 
asthma have clearly demonstrated increased numbers of 
eosinophils and mast cells in the affected airways. Other 
cell types are also known to contribute to the inflamma- 
tory events, including T lymphocytes and macrophages 
(8). All of these cells are lknown to have a crucial role in 
chronic airway inflammation through secretion of pre- 
formed and newly synthesized mediators that act either 
directly on the airway (9,lO) or indirectly through neural 
mechanisms (4,ll). Mucosal inflammation is characterized 
by increased T lymphocyte activation, mast cell degranu- 
lation and accumulation of activated eosinophils in the 
airways. These markers correlate with both variable air- 
way flow and airway hyper-responsiveness (12). To date, 
the exact relationship between individual inflammatory 
cells and their mediators, and hyper-responsiveness of 
the airways and clinical symptoms, remains unclear (8). 
There is also evidence which points to a pro-inflamma- 
tory role for structural cells in asthma, including 
epithelial and endothelial cells, fibroblasts and airway 
smooth muscle (8). The development of hyper- 
responsiveness is at least in part determined by epithelial 
injury, and this can be mediated by immunological and 
non-immunological mechanisms (II). 
Thus, all of these cell types are important target cells 
in the treatment of asthma and current anti-inflamma- 
tory corticosteroid therapy is thought to have direct in- 
hibitory actions on many of the inflammatory cells 
implicated in asthma (see Figure I). 
Eosinophils 
The eosinophils are the most characteristic inflamma- 
tory cells in bronchial biopsies taken from asthma 
patients and may be seen in the submucosal and epithelial 
layers. Activated eosinophils have been associated with 
tissue destruction (13). Eosinophils present in the airways 
are recruited from bronchial circulation after specific 
interaction with adhesion molecules expressed on the 
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Figure I. Cellular mechanisms Involved in airway inflammation 
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endothelium (9). Eosinophil mediator secretion in asthma 
has been confirmed by BAL, which shows increased con- 
centrations of granule-derived basic proteins (14). It is 
unlikely that cytokine secretion from the eosinophils or 
mast cells is the primary source of cytokines involved in 
the EAR, since it is the macrophages-acting as antigen 
presenting cells-that release the ‘first wave’ of cyto- 
kines. These cytokines then act on the epithelial cells to 
release a second wave of cytokines (IO). Eosinophils have 
been shown to selectively damage the bronchial epi- 
thelium through the release of mediators such as the ba- 
sic proteins contained in specific eosinophil granules and 
active oxygen radicals (9). 
1 lymphocytes 
T lymphocytes may also have an important role in initiat- 
ing early inflammatory events in the airways. Activated T 
helper (CD4+) lymphocytes are present in bronchial 
biopsy specimens and BAL fluid of asthma patients (II, 
13,15). The degree of activation of T lymphocytes in BAL 
fluid correlates with both the number of eosinophils in 
BAL fluid, as well as with the severity of symptoms and 
the degree of bronchial hyper-responsiveness (15). TheT 
helper lymphocytes have been classified into subgroups 
of cells which release different patterns of cytokines and 
so mediate the allergic response of asthma.Th2 type cells 
release a pattern of cytokines that are involved in allergic 
inflammation, including IL-4,lL-5, IL-9 and 11-13. In atopic 
individuals, the balance is tipped in favour of Th2 cells. 
Mast cells 
Increased numbers of mast cells have been identified in 
the bronchial epithelium using electron microscopy and 
BAL (9). In normal airways the number of mast cells in- 
creases towards the periphery of the lung, a region not 
accessible to endobronchial biopsy. However, the lungs of 
patients who have died from asthma show a substantial 
increase in mast cells, particularly outside the airway 
smooth muscle (9). The change in distribution of the 
mast cells within the asthmatic lung and the correlation 
between the number of mast cells and disease severity 
strongly support a role for mast cells in the pathophysi- 
ology of the disease (9,l6). Current evidence also provides 
a case for mast cell-derived histamine as the major com- 
ponent of adenosine-induced bronchoconstriction (16). 
Mast cells may also have a role in persistent or chronic 
inflammatory responses through the release of multi- 
functional cytokines. The evidence which supports this 
hypothesis includes the localization of immunoreactivity 
for 11-3, 11-4, 11-5, IL-6 and GM-CSF to mast cells in hu- 
man bronchial biopsies (16). Mast cells, in normal and 
asthmatic airways, contain tryptase as their major neu- 
tral protease. Tryptase is localized within the mast cells 
and has been used as a marker of mast cell degranulation. 
Increased concentrations of this protease have been 
found in lavage fluid in asthma patients (9). 
Macrophages 
Macrophages secrete cytokines, including IL- I, inter- 
feron-y, TNF-a, IL-6 and IL-8 (II). As effector cells they 
have additional pro-inflammatory functions in airway 
inflammation, being involved in the removal of cellular deb- 
ris and having the ability to migrate to sites of inflamma- 
tion (II). Their ability to secrete bioactive lipids, platelet- 
activating factors, reactive oxygen species, nitric oxide 
and nitrates has beneficial effects on vascular smooth mus- 
cle tone and bronchial epithelial cells, and possibly on bron- 
chial smooth muscle tone (II). However, macrophages may 
also inhibit allergic inflammation through the secretion of 
various inhibitory mediators, including prostaglandin Ez 
and IL- lO.The secretion of these inhibitory mediators may 
be impaired in patients with asthma (17). 
Structural cells 
The constituent cells of the airway, including fibroblasts, 
endothelial cells and epithelial cells, also contribute to 
the inflammatory process by releasing inflammatory 
mediators such as cytokines and chemokines (I). 
Airway microvascular leakage is another important 
component of airway inflammation which contributes 
to airway oedema and causes obstruction, bronchial hy- 
per-responsiveness and the formation of mucus plugs in 
the peripheral airways. Exuded plasma, via plasma me- 
diators, also adds to airway inflammation and airway nar- 
rowing (18). 
ASTHMATHERAPY: LINKING 
MECHANISM OF ACTION TO 
CLINICAL EFFICACY 
Anti-leukotriene drugs 
Leukotrienes are inflammatory mediators formed from 
arachidonic acid via the 5-lipoxygenase pathway. The cy- 
steinyl leukotrienes LTC4, LTD4 and LTE4 are potent 
bronchoconstrictors that have several biological actions 
in the pathogenesis of asthma, including increased vascu- 
lar permeability, formation of oedema and enhanced mu- 
cus production. Currently available anti-leukotriene 
drugs can act by decreasing the production or action of 
leukotrienes and they are the first agents used in the 
treatment of asthma to target specific steps in the in- 
flammatory pathway rather than the general suppressive 
effect of corticosteroids. 
Although studies suggest that anti-leukotriene drugs 
may be beneficial in asthma (l9), more recent studies 
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show that they are much less effective than very low 
doses of inhaled corticosteroids and are therefore not a 
substitute as first-line therapy (20).They are also less ef- 
fective than long-acting inhaled jIz-agonists as add-on 
therapy in asthma (21). 
Long-acting &agonists 
The /&-agonists are very effective bronchodilators, 
and short-acting inhaled Pa-agonists provide rapid 
relief of asthma symptoms. Formoterol and salmeterol 
are currently the only long-acting inhaled ,!z-agonists 
available for use in asthma patients, and they provide 
bronchodilation for at least I2 hours. This longer 
duration of action makes the long-acting /&-agonists 
suitable for maintenance therapy and the control of 
nocturnal asthma symptoms (22). Formoterol and 
salmeterol also have a higher affinity for j&-adrenocep- 
tors than salbutamol. Although formoterol and sal- 
meterol belong to the same class of long-acting 
P-agonists, they are very different pharmacologically. 
Salmeterol is a partial agonist at Pz-adrenoceptors 
whereas formoterol is a full agonist with a higher level 
of intrinsic efhcacy at the /Ia-adrenoceptor, giving a 
greater airway smooth muscle response, especially when 
muscle tone is increased (23). 
Mechanism ofaction and onset and duration ofaction 
The Pa-agonists bind to the /?a-adrenoceptor, causing ac- 
tivation of the receptor and subsequent stimulation of 
adenylate cyclase with the formation of cyclic AMP Cyc- 
lic AMP acts as an intracellular mediator to relax the 
bronchial smooth muscle and thus achieves bronchodi- 
lation. Cyclic AMP also inhibits the release of inflamma- 
tory mediators from mast cells (22,24). 
Formoterol and salmeterol are derived from a substi- 
tuted catecholamine ring structure with an extended hy- 
drophobic side-chain. Anderson (25) has proposed the 
plasmalemma diffusion microkinetic hypothesis to ex- 
plain the mode of action of long-acting b-agonists in the 
immediate vicinity of the Pz-adrenoceptor. Formoterol, a 
moderately lipophilic compound, is partitioned between 
the aqueous phase and the lipid membrane. In the aque- 
ous phase, formoterol is available to activate the recep- 
tor rapidly; however, sufficient formoterol is retained 
and subsequently released from the membrane to ac- 
count for its long duration of action. Salmeterol, on the 
other hand, which is highly lipophilic, has a partition 
equilibrium in favour of the lipid compartment. In this 
case, most of the agonist passes into the lipid membrane 
and there is little available to activate the receptor, thus 
accounting for the slow onset of action (25). Bronchodi- 
lation begins within 3 minutes of inhalation of formoterol 
12 pg, which compares well with the short-acting 
/I-agonists, and is maximal within 60 minutes. After a si- 
milar inhalation of salmeterol 5Opg, however, response 
begins after IO minutes and has a later peak (24). 
In addition to relaxing bronchial smooth muscle, the 
long-acting &agonists also have some anti-inflamma- 
tory properties, although they are not effective on the 
same inflammatory responses that are so effectively sup- 
pressed by corticosteroids (18). Using a guinea-pig model, 
Tokuyama et al, showed that topical formoterol was an 
effective inhibitor of histamine-induced airway microvas- 
culature leakage and airflow obstruction. Formoterol 
was 35 times more potent than salbutamol (18). In a re- 
cent double-blind, randomized, placebo-controlled 
study to investigate the effects of a single dose of inhaled 
formoterol or salbutamol viaTurbuhaler@ on airway re- 
sponsiveness to AMP and histamine, we showed that for- 
moterol had a probable mast cell-stabilizing effect in 
patients with mild asthma, whereas salbutamol did not 
(26). In a second study in mild atopic asthma patients, for- 
moterol significantly reduced the number of submucosal 
mast cells compared with pre-treatment, with a similar 
trend for eosinophils (27). 
The long-term use of &agonists is associated with a 
desensitization of the flz-adrenoceptor (23).Tolerance to 
the bronchoprotective and bronchodilator effects of j?z- 
agonists has been described by several authors (28-30). 
While tolerance to the bronchoprotective effect ap- 
pears well established, tolerance to the bronchodilator 
properties of long-acting /&-agonists is more conten- 
tious. Some studies report tolerance to the acute 
bronchodilatory response within 4 weeks of regular 
treatment and others show sustained improvements in 
indices of airway obstruction for up to 12 months (31-34). 
The down-regulation of pulmonary Pz-adrenoceptors, 
with a concomitant decrease in flz-adrenoceptor mRNA 
expression, has been reported after long-term flz-agon- 
ist monotherapy (2).The full clinical significance of this is 
unclear, since other researchers have shown that long- 
term corticosteroids up-regulate /3z-adrenoceptors 
(35). Assuming patients with asthma receive anti-inflam- 
matory medication in the form of corticosteroids, po- 
tential receptor down-regulation may be prevented. 
Corticosteroids 
Corticosteroids are the most effective treatment for 
asthma currently available, and inhaled corticosteroids 
are now the mainstay of asthma therapy. The recognition 
of an early role for inflammation in the pathogenesis of 
asthma has led to the introduction of inhaled cortico- 
steroid treatment at an earlier stage in therapy. In fact, 
inhaled corticosteroids are now recommended for all 
patients who have symptoms more than twice weekly 
(5) or who require an inhaled /&-agonist more than once 
daily (6). 
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Corticosteroids produce their effect on responsive 
cells in asthmatic airways by activating glucocorticoid 
receptors (GR) to directly or indirectly regulate the 
transcription of certain target genes (I, 36). The GR are 
widely distributed within the human lung, with the great- 
est concentrations being located in the airway epithelial 
cells and bronchial vascular endothelial cells (I). 
Corticosteroids decrease the number and activation 
status of a range of inflammatory cells, including airway 
eosinophils,T lymphocytes, macrophages, dendritic cells 
and mucosal mast cells (36,37). 
The number of circulating eosinophils is effectively re- 
duced by corticosteroid treatment and this may be due 
to a direct effect on eosinophil production in the bone 
marrow (I). Inhaled corticosteroids also inhibit the 
night-time increase in circulating eosinophils in patients 
with nocturnal asthma, with a concomitant reduction in 
nocturnal asthma symptoms. There is a marked reduc- 
tion in the number of degranulated eosinophils after cor- 
ticosteroid therapy, which is thought to result via 
inhibition of cytokine production in the airways (1,9). 
The permissive action of cytokines such as GM-CSF 
and IL-5 on eosinophil survival is inhibited by corticoster- 
oids and this contributes to a reduction in airway eosino- 
phils (I). Corticosteroids are direct inhibitors of 
mediator release from eosinophils and weakly inhibit 
the release of reactive oxygen species and eosinophil 
basic proteins that cause bronchial damage (I). Addition- 
ally, corticosteroids block the release of cytokines fromT 
lymphocytes, thus reducing the recruitment and survival 
of several inflammatory cells involved in airway inflam- 
mation (I). 
The regular use of corticosteroids in steroid-depen- 
dent and non-steroid-dependent asthmatics is asso- 
ciated with a decrease in airway responsiveness. This 
improvement is reversible and the protective effect dis- 
appears after withdrawal of corticosteroid therapy, high- 
lighting the need to continue this therapy (38). 
Clinical experience with budesonide and 
formoterol 
Clinical studies have shown that budesonide IOO-8OOpg 
twice daily administered byTurbuhaler@ is effective and 
improves lung function in a dose-response fashion (39). 
However, in a previous study in patients with moderate 
asthma there was no clear dose-response for improve- 
ments in lung function with inhaled corticosteroids (40). 
Doubling of the dose of inhaled corticosteroids in uncon- 
trolled asthma is a frequent solution to gaining control of 
asthma symptoms, but this rationale is not well sup- 
ported in the literature. 
The efficacy and safety of budesonide have been ex- 
tensively covered in earlier reviews (41,42). More recently, 
budesonide has been shown to be effective in a number 
of studies of patients with mild to moderate asthma (43- 
46). Budesonide therapy is also effective once or twice 
daily. In a number of studies, a single daily dose of 
budesonide was as effective as twice-daily dosing in 
improving lung function and asthma symptoms (44, 
47-49). The therapeutic control of asthma symptoms 
achieved by budesonide over a range and frequency of 
doses makes it an ideal agent in the treatment of asthma, 
which varies in severity over time. 
The efficacy of budesonide has also been demon- 
strated in children with asthma or recurrent wheezing 
(49-53). Short- and long-term studies have been carried 
out to evaluate the effect of budesonide on adrenal sup- 
pression and bone growth in children (54-56). Budeso- 
nide was well tolerated in these patients and there were 
no significant adrenal suppression or adverse effects re- 
lated to bone growth (54-56). 
The efficacy of formoterol has been demonstrated in 
both short- and long-term randomized, placebo-con- 
trolled trials. In one short-term study (n =43; 2 weeks), 
formoterol l2pg was more effective than formoterol 
6yg or placebo (57). In a second larger study (n = l56), 
formoterol 6, 12 and 24pg significantly reduced asthma 
scores and the need for supplementary medication (58). 
Several long-term studies ranging from I2 to 25 months 
have also demonstrated the efficacy of formoterol l2,~g 
and 24,ug twice-daily (58-61). In all of these studies, 
patients treated with formoterol showed an improve- 
ment in lung function and improved asthma control 
without the need to increase the dose of formoterol or 
that of corticosteroids. 
Inhaled formoterol is also efficacious in children with 
asthma; however, the majority of the early studies were 
of short duration (62). In one long-term study (n = 82; I 
year), clinical efficacy variables and lung function im- 
proved over the course of the study with no evidence 
of tachyphylaxis (59). 
The efficacy of formoterol in addition to inhaled corti- 
costeroid therapy has also been demonstrated in a long- 
term study (n = 852) in patients with poorly controlled 
asthma despite regular inhaled corticosteroid therapy 
(34). In this study formoterol plus budesonide treatment 
improved asthma symptoms and reduced the number of 
exacerbations more effectively than increasing the dose 
of budesonide alone. The improvements seen in the for- 
moterol plus budesonide treated patients were achieved 
without lessening the control of asthma. Additionally, 
there is no evidence that the course of exacerbations of 
asthma is different during treatment with formoterol 
(63). Nor is there any evidence that formoterol masks in- 
flammation, as low-dose budesonide plus formoterol and 
high-dose budesonide were equally effective in suppres- 
sing sputum eosinophils (64). 
Other studies support the findings that the addition of 
a low-dose, long-acting /&agonist to low- or moderate- 
dose corticosteroids is as effective or more effective 
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than high-dose corticosteroids, but without the long- 
term systemic effects associated with high corticoster- 
oid doses (31,65-68). 
THE FUTURE OF ASTHMATHERAPY 
Given the complex mechanisms involved in the patho- 
physiology of asthma, it is not surprising that asthma 
treatment is associated with a range of different ther- 
apies, all of which need to be carefully tailored for the 
individual patient. 
Indeed, new therapies have been added to asthma 
treatment as our understanding of the different aspects 
of the disease has increased. However, the use of multi- 
ple therapies necessitates a clear understanding of the 
mode of action of the drugs and any potential interac- 
tion or overlap of effect. For example, it is now clear that 
the long-acting P2-agonists and corticosteroids both 
have a controlling role in the treatment of asthma, but 
their cellular effects are complementary. Furthermore, 
there may be a positive interaction between these two 
classes of drugs, as corticosteroids may prevent toler- 
ance to long-acting fiz-agonists, and /&agonists may in- 
crease the molecular effects of corticosteroids (69). The 
efficacy of formoterol administered as needed suggests 
that the concomitant use of a short-acting Pz-agonist 
and formoterol has little clinical benefit. Acceptance of 
such an idea is an important step towards simplifying 
asthma management for both the doctor and patient. 
The use of multiple drugs in the treatment of asthma 
can make asthma management complex. From the point 
of view of the patient, the more complicated their treat- 
ment the more difficult it is for them to adhere to their 
treatment plan. Without a clear understanding of their 
disease or while in a distressed state, a patient may even 
take the wrong medication by mistake. Thus treatment 
developments that pave the way to simplifying 
asthma treatment are a welcome addition to asthma 
therapy. One such development is the combination of an 
inhaled corticosteroid and long-acting ,!I*-agonist in asin- 
gle inhaler. 
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